Company: RNAC
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001453687-25-000060
Chunk: 141

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1A
Chunk 141
---
 price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.

The trading price of our common stock is likely to be volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the price at which you purchased. The market price for our common stock may be influenced by many factors, including:

•the success of competitive products or technologies;

•results or progress, or changes in approach or timelines, of clinical trials of our product candidates or those of our competitors;

•failure or discontinuation of any of our development programs;

•commencement of, termination of, or any development related to any collaboration or licensing arrangement;

•regulatory or legal developments in the United States and other countries;

•development of new product candidates that may address our markets and make our product candidates less attractive;

•changes in physician, hospital or healthcare provider practices that may make our product candidates less useful;

•announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;

•announcement or market expectation of additional financing efforts;

•developments or disputes concerning patent applications, issued patents or other proprietary rights;

•the recruitment or departure of key personnel;

•the level of expenses related to any of our product candidates or clinical development programs;

•failure to meet or exceed financial estimates, projections or development timelines of the investment community or that we provide to the public;

•the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;

•actual or expected changes in estimates as to financial results, development timelines or recommendations by securities analysts;

•variations in our financial results or those of companies that are perceived to be similar to us;

•changes in the structure of healthcare payment systems;

•sale of common stock by us or our stockholders in the future as well as the overall trading volume of our common stock;

•changes in the composition of our stockholder base;

•activity in the options market for shares of our common stock;

•market conditions in the pharmaceutical and biotechnology sectors;

•general economic, industry and market conditions; and

•the other factors described in this “Risk Factors” section